About Dr. Gao Xin (高鑫)
Dr. Gao Xin is a Professor and Chief Physician in the Department of Endocrinology at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine — one of China's most prestigious academic medical centers and a national leader in endocrinology and metabolic disease. A widely recognized authority in non-alcoholic fatty liver disease (NAFLD/NASH), diabetes mellitus, and metabolic syndrome, Dr. Gao has dedicated her career to understanding and treating the complex interplay between metabolic dysfunction, liver disease, and cardiovascular risk.
Dr. Gao leads a high-volume endocrinology clinic at Ruijin Hospital and is a principal investigator in multiple national research programs focused on the metabolic basis of fatty liver disease and type 2 diabetes. Her work bridges clinical endocrinology and translational research, offering patients access to cutting-edge diagnostic protocols and emerging therapies.
Core Clinical Specializations
1. Non-Alcoholic Fatty Liver Disease (NAFLD / NASH)
Conditions Treated:
- Non-alcoholic fatty liver disease (NAFLD) — simple steatosis to advanced fibrosis
- Non-alcoholic steatohepatitis (NASH) with and without cirrhosis
- Metabolic-associated fatty liver disease (MAFLD)
- NAFLD-related hepatocellular carcinoma risk stratification
- NAFLD in the context of type 2 diabetes, obesity, and dyslipidemia
Diagnostic Approach:
- Non-invasive fibrosis assessment (FIB-4, NFS, ELF score)
- Transient elastography (FibroScan) for liver stiffness measurement
- MRI-PDFF (proton density fat fraction) for quantitative liver fat assessment
- Liver biopsy coordination where clinically indicated
- Comprehensive metabolic profiling (insulin resistance, lipid panel, adipokines)
Treatment Approaches:
- Structured lifestyle intervention programs (diet, exercise, behavioral modification)
- Pharmacological management: GLP-1 receptor agonists, SGLT-2 inhibitors, pioglitazone, vitamin E
- Emerging therapies: access to clinical trials for NASH-specific agents (FXR agonists, THR-β agonists)
- Multidisciplinary coordination with hepatologists and bariatric surgeons for advanced cases
2. Type 2 Diabetes & Insulin Resistance
Conditions Treated:
- Type 2 diabetes mellitus (newly diagnosed and long-standing)
- Prediabetes and impaired glucose tolerance
- Insulin resistance and metabolic syndrome
- Diabetic complications: nephropathy, neuropathy, retinopathy, cardiovascular disease
- Diabetes in the context of NAFLD, obesity, and PCOS
Treatment Approaches:
- Individualized glycemic management with treat-to-target protocols
- Advanced insulin therapy (basal-bolus, insulin pump / CSII)
- GLP-1 receptor agonists and SGLT-2 inhibitors for cardiorenal protection
- Continuous glucose monitoring (CGM) interpretation and optimization
- Structured diabetes education and self-management support
3. Obesity & Metabolic Syndrome
Conditions Treated:
- Obesity (BMI ≥28 kg/m² by Asian criteria) with metabolic complications
- Metabolic syndrome (central obesity, hypertriglyceridemia, low HDL, hypertension, hyperglycemia)
- Dyslipidemia (hypertriglyceridemia, mixed hyperlipidemia)
- Hyperuricemia and gout in the metabolic context
- Polycystic ovary syndrome (PCOS) with insulin resistance
Treatment Approaches:
- Medical weight management with GLP-1 receptor agonists (semaglutide, liraglutide)
- Structured very low calorie diet (VLCD) and intermittent fasting protocols
- Coordination with bariatric surgery team for eligible patients
- Comprehensive cardiovascular risk reduction strategies
4. General Endocrinology
Conditions Treated:
- Thyroid disorders (hypothyroidism, hyperthyroidism, thyroid nodules)
- Adrenal disorders (Cushing's syndrome, adrenal incidentaloma, primary aldosteronism)
- Pituitary disorders (hyperprolactinemia, growth hormone deficiency, panhypopituitarism)
- Osteoporosis and metabolic bone disease
- Type 1 diabetes and latent autoimmune diabetes in adults (LADA)
Academic Achievements & National Leadership
- Professor of Medicine, Shanghai Jiao Tong University School of Medicine
- Chief Physician, Department of Endocrinology, Ruijin Hospital
- Member, Chinese Diabetes Society — NAFLD and Metabolic Disease Working Group
- Member, Chinese Society of Endocrinology
- Principal investigator on multiple NSFC-funded research projects in NAFLD pathogenesis and metabolic disease
- Author of over 90 peer-reviewed publications in Chinese and international endocrinology and hepatology journals
- Invited speaker at major international conferences (EASL, ADA, ENDO, APASL)
Why International Patients Choose Dr. Gao Xin
- NAFLD/NASH expertise: Dr. Gao is one of China's leading clinician-researchers in metabolic fatty liver disease, offering access to the latest non-invasive diagnostics and emerging pharmacological therapies.
- Integrated metabolic care: Rather than treating diabetes, fatty liver, and obesity in isolation, Dr. Gao addresses the underlying metabolic dysfunction driving all three conditions simultaneously.
- Access to clinical trials: Ruijin Hospital participates in international clinical trials for NASH-specific therapies, offering eligible patients access to investigational agents not yet widely available.
- Multidisciplinary approach: Complex cases are managed jointly with hepatologists, cardiologists, bariatric surgeons, and dietitians to ensure comprehensive, coordinated care.
- Cost-effectiveness: World-class endocrinology and metabolic disease management at a fraction of the cost compared to equivalent centers in the US, UK, or Australia.
Treatment Protocols & Patient Journey
Step 1: Pre-Consultation Review
CMCS Shanghai coordinates a review of all available records — including laboratory results (HbA1c, fasting glucose, lipid panel, liver function tests, insulin levels), imaging (ultrasound, FibroScan, MRI-PDFF), and prior treatment history — before your first appointment with Dr. Gao.
Step 2: In-Person Consultation at Ruijin Hospital
Your consultation includes a comprehensive metabolic assessment, review of laboratory and imaging findings, and a detailed discussion of diagnosis and individualized treatment options. CMCS provides full medical interpretation throughout.
Step 3: Diagnostic Workup
Where indicated, Dr. Gao's team arranges additional investigations including non-invasive liver fibrosis assessment (FibroScan, MRI-PDFF), insulin resistance testing (HOMA-IR, oral glucose tolerance test), and cardiovascular risk profiling. CMCS coordinates all logistics.
Step 4: Treatment Initiation & Monitoring
Dr. Gao establishes a structured treatment plan including medication protocols, dietary and lifestyle recommendations, and monitoring schedules. For patients returning home, a detailed management plan is prepared for your local physicians, including specific targets and follow-up intervals.
Step 5: Repatriation & Ongoing Coordination
CMCS prepares a comprehensive medical summary in English for your home country physicians, including all investigation results, diagnosis, treatment plan, and follow-up recommendations. Remote follow-up consultations can be arranged where clinically appropriate.
Frequently Asked Questions
Can Dr. Gao see international patients without a Chinese referral letter?
Yes. CMCS Shanghai facilitates direct access to Dr. Gao's clinic at Ruijin Hospital for international patients. Prior laboratory results and imaging are helpful but a formal referral letter is not mandatory.
Is NAFLD/NASH reversible with treatment?
Early-stage NAFLD (simple steatosis and mild NASH without advanced fibrosis) is potentially reversible with sustained lifestyle modification and appropriate pharmacological therapy. Advanced fibrosis (F3-F4) is less reversible but progression can be halted and cardiovascular risk reduced. Dr. Gao's team uses non-invasive fibrosis staging to guide treatment intensity and monitoring frequency.
What is the difference between NAFLD and MAFLD?
MAFLD (metabolic-associated fatty liver disease) is a newer diagnostic framework that emphasizes the metabolic drivers of fatty liver disease (obesity, type 2 diabetes, metabolic syndrome) rather than simply excluding alcohol as a cause. Dr. Gao's practice uses both frameworks and tailors management to the individual patient's metabolic profile.
Can GLP-1 receptor agonists (e.g., semaglutide) be prescribed at Ruijin Hospital?
Yes. GLP-1 receptor agonists including semaglutide (Ozempic/Wegovy) and liraglutide are available at Ruijin Hospital and are used by Dr. Gao's team for eligible patients with type 2 diabetes, obesity, and NAFLD/NASH. Prescribing follows Chinese national guidelines and individual clinical assessment.
What languages does Dr. Gao's team communicate in?
Dr. Gao's clinical team communicates primarily in Mandarin Chinese. CMCS Shanghai provides full English medical interpretation for all consultations and follow-up discussions.
Schedule Your Consultation
If you are managing non-alcoholic fatty liver disease, type 2 diabetes, obesity, or metabolic syndrome and are seeking expert care in Shanghai, CMCS Shanghai can arrange a consultation with Dr. Gao Xin at Ruijin Hospital.
- 📧 Email: contract@medicalsh.com
- 💬 WeChat: gezhanglao
- 🌐 Website: medicalsh.com
CMCS Shanghai — Connecting international patients with China's top specialists, from first inquiry to full recovery.
Disclaimer: This profile is intended for educational and informational purposes only. CMCS Shanghai is a medical concierge service and does not provide direct medical care. All clinical decisions are made by licensed physicians at accredited hospitals.
0 comentarios